ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent
Authors:
- 5 May 2021
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (5) , 2653-2660
Abstract
Background/Aim: To predict the efficacy of platinum-containing chemotherapy, ERCC1 expression levels were investigated. Studies have shown changes in the performance of anti-ERCC1 antibodies; therefore, predicting chemotherapy efficacy by immunohistochemical assessment of ERCC1 is controversial. Patients and Methods: Twenty-eight patients who received platinum-containing chemotherapy and underwent computed tomography evaluation 6-9 weeks after therapy initiation were retrospectively identified. The tumor samples were evaluated in 2012 and 2018 using the latest anti-ERCC1 antibodies available at those times. Results: In 2012, the ERCC1 H-score was significantly higher in patients with disease progression than in patients without disease progression (p=0.019). Although the same trend was shown in 2018, there were some inconsistent results between the 2012 and 2018 samples. Conclusion: Patients with tumors showing low ERCC1 expression had a better disease control rate on platinum-containing chemotherapy. However, since the performance of the antibody changed over time, standardized technology to evaluate ERCC1 expression is needed.Keywords
This publication has 19 references indexed in Scilit:
- Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)Journal of Clinical Oncology, 2017
- Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based ChemotherapyJournal of Clinical Oncology, 2010
- Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non–Small-Cell Lung Cancer Treated With Carboplatin and GemcitabineJournal of Clinical Oncology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal CancerClinical Cancer Research, 2005
- ERCC1 and Clinical Resistance to Platinum-Based TherapyClinical Cancer Research, 2005
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2004
- Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.International Journal of Oncology, 2000
- A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissuesMutation Research/Mutation Research Genomics, 1997